ArticleScientific reports2025
ATF3 overexpression is associated with cardiac hypertrophy and electrical dysfunction accompanied by enhanced cardiac cell proliferation in zebrafish.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Activating transcription factor 3 (ATF3) is a crucial regulator of gene expression in response to physiological stress across various tissues. Abnormal ATF3 expression is associated with cardiac dysfunction; however, the mechanisms by which it affects cardiac pathology remain unclear. In this study, we developed a cardiac-specific ATF3-expressing zebrafish line, Tg(myl7:ATF3), using a well-established vertebrate model for cardiovascular research to investigate the role of human ATF3 in the zebrafish heart. We conducted morphological assessments, immunofluorescence staining, electrocardiography, and transcriptome analysis on transgenic and wild-type zebrafish. Compared to wild-type siblings, Tg(myl7:ATF3) zebrafish exhibited significant pathophysiological changes, including cardiac hypertrophy and features resembling hypertrophic cardiomyopathy. Histological analysis revealed increased fibrotic scarring and disorganized sarcomeres. Electrocardiogram measurements indicated that ATF3 overexpression induced symptoms resembling long QT syndrome, suggesting electrical dysfunction. Transcriptome analysis demonstrated downregulation of apoptosis-related genes and upregulation of proliferation-related genes in the hearts of transgenic zebrafish. These findings suggest that ATF3 expression is associated with cardiac hypertrophy accompanied by increased proliferation of cardiac cells, including cardiomyocytes. The findings of this study provide novel insights into the role of ATF3 in cardiovascular disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.